You're signed outSign in or to get full access.
Propel Bio Management, LLC
PROPEL BIO MANAGEMENT, LLC is a Delaware limited liability company headquartered in Los Angeles, California. Founded in 2022, it is owned by Leen Kawas and is focused on supporting life sciences and biotechnology companies. The firm acts as an investment adviser and typically manages a small team (between 6 and 7 employees) with significant investment and scientific expertise. Propel Bio Management, LLC serves entrepreneurial founders in the biotech and life science sectors, advancing groundbreaking technologies and therapies to improve human health.
Investment Strategy
Propel Bio Management, LLC drives its investment strategy by leveraging deep scientific and business expertise to invest in entrepreneurial life sciences companies. The firm focuses on companies developing disruptive therapies and technologies with the goal of advancing human health. Propel Bio supports its portfolio companies with an ecosystem of experts spanning life science industry, finance, and investment disciplines, aiming to help founders fulfill urgent missions in healthcare innovation. Their approach emphasizes purposeful and efficient advancement of science, supporting founders from early development to commercialization.
Latest 13F Filing Activity
Propel Bio Management, LLC filed their most recent 13F report on Jun 30, 2025 disclosing 12 equity positions with a total 13F market value of $82M. The fund increased holdings in Achieve Life Sciences Inc., Akero Therapeutics Inc., Abeona Therapeutics Inc. among other positions. Propel Bio Management, LLC reduced exposure to Madrigal Pharmaceuticals, Avidity Biosciences Inc., Plains GP Holdings Lp-cl among others.
Top Holdings
Equity Positions (12)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
P PAGP | PLAINS GP HOLDINGS LP-CL | 30.01% | $24.7M | 1,272,360 | $19.03 | $19.43 | -$2.5M |
A ACHV | ACHIEVE LIFE SCIENCES INC | 16.88% | $13.9M | 6,153,091 | $3.18 | $2.26 | +$7.4M |
A AKRO | AKERO THERAPEUTICS INC | 14.82% | $12.2M | 228,884 | $24.08 | $53.36 | +$2.9M |
P PHAT | PHATHOM PHARMACEUTICALS I | 10.74% | $8.9M | 922,927 | $9.21 | $9.59 | +$1.7M |
| ABEONA THERAPEUTICS INC | 6.71% | $5.5M | 974,022 | $4.69 | $5.66 | +$2.6M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more